ArticleDiscover oncology2026
miR-34a-5p-mediated inhibition on the KRT5/DSP axis blunts cancer stem cell properties and cisplatin resistance in non-small cell lung cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The survival rate of patients diagnosed with non-small cell lung cancer (NSCLC) are significantly influenced by drug resistance and metastasis with cancer stem cells (CSCs). MicroRNAs (miRNAs) impact on the progression of various human diseases, including different types of cancers. This research seeks to clarify how miR-34a-5p influences CSC characteristics and resistance to cisplatin (DDP) in NSCLC. Initially, the levels of expression for miR-34a-5p, KRT5, and DSP were analyzed in both NSCLC tissue samples and cell lines through RT-qPCR and western blot techniques. Subsequently, sphere formation assays, CCK-8 assays, and flow cytometry tests were carried out to evaluate CSCs and their resistance to DDP in NSCLC. The expression of genes related to stemness, such as SOX2, CD133, and ALDH, was assessed using western blotting methods. Functional experiments were also conducted to investigate the regulatory mechanisms linked to miR-34a-5p, KRT5, and DSP. Finally, the effect of miR-34a-5p on the CSC phenotype and resistance to DDP was validated using a xenograft mouse model. Results showed that, in NSCLC patients, miR-34a-5p was found to be decreased, while KRT5 and DSP expressions were elevated. By targeting the KRT5/DSP axis, miR-34a-5p was shown to suppress CSC properties and enhance DDP sensitivity in NSCLC cells. miR-34a-5p directly bound to and inhibited KRT5, resulting in the downregulation of DSP expression. Furthermore, the overexpression of miR-34a-5p in mice resulted in reduced tumor growth. Collectively, this study elucidates the regulatory role of miR-34a-5p on CSC properties, providing insights that may aid in overcoming drug resistance in NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.